Lilly’s Alzheimer's and obesity results, outcomes for Novo Nordisk and oncology data for Merck & Co and Astrazeneca.
Both developers lay out ambitious plans for oral projects to rival injected GLP-1s, while Lilly strives to build on Mounjaro.
Hitting two targets with one molecule is all the rage in oncology, but Roche and others have taken this work into other disease areas.
With four pivotal tiragolumab readouts, Roche’s 2022 will not only be the year of Alzheimer’s.
Lilly pips Pfizer to the big pharma top spot on share price performance, while Covid-19 drives the largest risers elsewhere.
A handful of huge success stories mask disappointing performances elsewhere, with small caps and Asian pharma firms feeling the pain.
Moderna is the standout gainer, but the stragglers are becoming more apparent as the pandemic tide retreats.